BNTX250516C145000
- 0.05
- -0.11-68.75%
BioNTech Newsroom
Express News | BioNTech SE : HSBC Cuts Target Price to $121 From $122
Earnings Preview: BioNTech to Report Financial Results Pre-market on May 05
Leerink Partners Maintains BioNTech(BNTX.US) With Buy Rating
Deutsche Bank Remains a Buy on BioNTech SE (BNTX)
Pfizer Hints at Acquisitions to Boost Obesity Pipeline After Trial Setback
Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline
Why Is Summit Therapeutics Stock Trading Higher On Monday?
Jefferies Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $149
J.P. Morgan Maintains BioNTech(BNTX.US) With Hold Rating
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading
BioNTech SE: Promising Clinical Trials and Diversified Oncology Pipeline Support Buy Rating
BioNTech SE (BNTX) Receives a Hold From J.P. Morgan
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), BeiGene (ONC) and BioNTech SE (BNTX)
Jefferies Reaffirms Their Buy Rating on BioNTech SE (BNTX)
Notable Healthcare Headlines for the Week: Merck, Roche and Bausch Health in Focus
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Novavax Told by FDA to Conduct Additional Study for COVID Vaccine - Report
BioNTech SE ADR Falls 15.4%, Underperforms Market
Merck Gains After Latest Survival Data for Summit's Cancer Drug
Trending Stocks Today | Baijiayun Soars 74.33%